Company intelligence / Profile preview

Drusolv Therapeutics

Philadelphia, Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Clinical

Overview

Drusolv Therapeutics develops Ocustatin™, a novel, high-dose oral atorvastatin formulation targeting intermediate age-related macular degeneration. The company aims to prevent progression to late-stage vision loss by restoring RPE phagocytosis and reducing drusen accumulation. A prior proof-of-concept study showed promising results, and the company has been funded to complete formulation work and prepare an IND for a definitive Phase 2 clinical trial. There are currently no approved drugs for this stage of AMD, making Ocustatin™ potentially first-in-class.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (specifically high-dose statins/atorvastatin)
Industry: Biotech

Partnerships

Co-investigators at Harvard University involved in prior proof-of-concept studies

Beyond the preview

Go deeper on Drusolv Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Drusolv Therapeutics.

Explore the full profile